A straightforward tool for developing a raw material supply strategy for cell & gene therapies

Raw materials used in manufacturing processes for cell and gene therapies may carry a supply risk due to the unavailability of GMP-grade material, unique biological and chemical components, or limited supply options. This Expert Insight outlines a tool that allows an objective and straightforward assessment of supply risk for raw materials and identifies feasible options for mitigating such risk.

Please enter your email to access content Read now